Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 June 2007, Vol. 109, No. 11, pp. 4599-4606.
Prepublished online as a Blood First Edition Paper on February 13, 2007; DOI 10.1182/blood-2006-08-039859.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix
Right arrow All Versions of this Article:
blood-2006-08-039859v1
109/11/4599    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiestner, A.
Right arrow Articles by Staudt, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiestner, A.
Right arrow Articles by Staudt, L. M.
Related Collections
Right arrow Neoplasia
Right arrow Gene Expression
Right arrow Free Research Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

PLENARY PAPER

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Adrian Wiestner1,2, Mahsa Tehrani2, Michael Chiorazzi1, George Wright1, Federica Gibellini2, Kazutaka Nakayama2, Hui Liu2, Andreas Rosenwald3, H. Konrad Muller-Hermelink3, German Ott3, Wing C. Chan4, Timothy C. Greiner4, Dennis D. Weisenburger4, Julie Vose4, James O. Armitage4, Randy D. Gascoyne5, Joseph M. Connors5, Elias Campo6, Emilio Montserrat6, Francesc Bosch6, Erlend B. Smeland7, Stein Kvaloy7, Harald Holte7, Jan Delabie7, Richard I. Fisher8, Thomas M. Grogan8, Thomas P. Miller8, Wyndham H. Wilson1, Elaine S. Jaffe1, Louis M. Staudt, for the Lymphoma/Leukemia Molecular Profiling Project1

1 Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; 2 Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD; 3 University of Würzburg, Germany; 4 University of Nebraska Medical Center, Omaha, NE; 5 British Columbia Cancer Center, Vancouver, BC, Canada; 6 Hospital Clinic, University of Barcelona, Spain; 7 Norwegian Radium Hospital, Oslo, Norway; 8 Southwest Oncology Group, San Antonio, TX

A gene expression signature of tumor proliferation rate in mantle cell lymphoma (MCL) is an overriding molecular predictor of the length of survival following diagnosis. Many strongly proliferative MCL tumors have exceptionally high cyclin D1 mRNA levels and preferentially express short cyclin D1 mRNA isoforms. We demonstrate here that these short mRNAs are cyclin D1a isoforms with truncated 3'UTRs, not alternatively spliced cyclin D1b mRNA isoforms. Among 15 MCL tumors with truncated cyclin D1 mRNAs, 7 had genomic deletions in the CCND1 3'UTR region. In 3 others, CCND1 contained point mutations that created premature polyadenylation signals, giving rise to 1.5-kb mRNAs lacking most of the 3'UTR. Both types of genomic alteration created transcripts lacking mRNA destabilization elements present in the wild-type cyclin D1a mRNA. Premature polyadenylation due to a 3'UTR mutation also was present in the Z-138 MCL cell line, which expressed both truncated and full-length cyclin D1a mRNAs. In these cells, the half-life of the short cyclin D1a mRNA was much longer than that of the full-length mRNA. We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
S. Bea, I. Salaverria, L. Armengol, M. Pinyol, V. Fernandez, E. M. Hartmann, P. Jares, V. Amador, L. Hernandez, A. Navarro, et al.
Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling
Blood, March 26, 2009; 113(13): 3059 - 3069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
S. J. Freemantle, Y. Guo, and E. Dmitrovsky
Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs
Cancer Prevention Research, January 1, 2009; 2(1): 3 - 6.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. A. Tucker, A. I. Kapanen, G. Chikh, B. G. Hoffman, A. H. Kyle, I. M. Wilson, D. Masin, R. D. Gascoyne, M. Bally, and R. J. Klasa
Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-{kappa}B, p53, bax, and p27 levels
Mol. Cancer Ther., April 1, 2008; 7(4): 749 - 758.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. A. O'Connor
Mantle Cell Lymphoma: Identifying Novel Molecular Targets in Growth and Survival Pathways
Hematology, January 1, 2007; 2007(1): 270 - 276.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020